Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
CEMI's Cash to Debt is ranked higher than
95% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. CEMI: No Debt )
Ranked among companies with meaningful Cash to Debt only.
CEMI' s Cash to Debt Range Over the Past 10 Years
Min: 0.02  Med: 27.45 Max: No Debt
Current: No Debt
Equity to Asset 0.72
CEMI's Equity to Asset is ranked higher than
68% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.58 vs. CEMI: 0.72 )
Ranked among companies with meaningful Equity to Asset only.
CEMI' s Equity to Asset Range Over the Past 10 Years
Min: -2.07  Med: 0.64 Max: 0.86
Current: 0.72
-2.07
0.86
F-Score: 4
Z-Score: 10.82
M-Score: -7.18
WACC vs ROIC
12.31%
-70.64%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -21.89
CEMI's Operating margin (%) is ranked lower than
61% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.67 vs. CEMI: -21.89 )
Ranked among companies with meaningful Operating margin (%) only.
CEMI' s Operating margin (%) Range Over the Past 10 Years
Min: -83.68  Med: -1.66 Max: 15.41
Current: -21.89
-83.68
15.41
Net-margin (%) -45.98
CEMI's Net-margin (%) is ranked lower than
65% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.36 vs. CEMI: -45.98 )
Ranked among companies with meaningful Net-margin (%) only.
CEMI' s Net-margin (%) Range Over the Past 10 Years
Min: -82.52  Med: -1.16 Max: 32.02
Current: -45.98
-82.52
32.02
ROE (%) -60.04
CEMI's ROE (%) is ranked lower than
73% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.35 vs. CEMI: -60.04 )
Ranked among companies with meaningful ROE (%) only.
CEMI' s ROE (%) Range Over the Past 10 Years
Min: -14522.12  Med: 3.12 Max: 67.84
Current: -60.04
-14522.12
67.84
ROA (%) -48.68
CEMI's ROA (%) is ranked lower than
72% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.35 vs. CEMI: -48.68 )
Ranked among companies with meaningful ROA (%) only.
CEMI' s ROA (%) Range Over the Past 10 Years
Min: -146.42  Med: -1.03 Max: 50.54
Current: -48.68
-146.42
50.54
ROC (Joel Greenblatt) (%) -49.44
CEMI's ROC (Joel Greenblatt) (%) is ranked lower than
54% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -13.16 vs. CEMI: -49.44 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CEMI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -597.6  Med: -1.05 Max: 84.31
Current: -49.44
-597.6
84.31
Revenue Growth (3Y)(%) 8.60
CEMI's Revenue Growth (3Y)(%) is ranked higher than
65% of the 136 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.30 vs. CEMI: 8.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CEMI' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 3.9 Max: 59.4
Current: 8.6
0
59.4
» CEMI's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-12)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

CEMI Guru Trades in

Q4 2015

CEMI Guru Trades in Q4 2015

Jim Simons 13,100 sh (New)
» More
Q1 2016

CEMI Guru Trades in Q1 2016

Jim Simons 13,900 sh (+6.11%)
» More
Q2 2016

CEMI Guru Trades in Q2 2016

Jim Simons 48,200 sh (+246.76%)
» More
» Details

Insider Trades

Latest Guru Trades with CEMI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:AMEX:VNRX, NAS:CDNA, NAS:VRML, NAS:AIQ, OTCPK:AVDX, NAS:PMD, OTCPK:EPGNY, OTCPK:ILIU, OTCPK:PRFMF, AMEX:PTN, NAS:CTSO, NAS:CGIX, NAS:OPGN, OTCBB:INIS, OTCPK:CBIS, NAS:TEAR, OTCPK:MHTX, OTCPK:SYGWF, NAS:GENE, NAS:CHEK » details
Chembio Diagnostics Inc develops, manufacture market & licenses rapid point of care diagnostic tests that detect infectious diseases. Its products are rapid tests for the detection of HIV 1/2 antibodies, & for the detection of HIV & Syphilis antibodies.

Chembio Diagnostics Inc was formed in 1985. The Company with its subsidiaries develops, manufactures and markets diagnostic tests that detect infectious diseases. The Company's main products presently commercially available are four rapid tests for the detection of HIV antibodies in whole blood, serum and plasma samples, all of which Employ lateral flow technology, and two of which were approved by the FDA in 2006. The Company's products are sold to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals and retail establishments both domestically and internationally. The Company's products are sold under its STAT PAK, SURE CHECK or DPP registered trademarks. The Company's HIV tests are qualitative (reactive/non-reactive) tests. Many of its competitors are substantially larger and have greater financial, research, manufacturing and marketing resources. The manufacturing and marketing of the Company's existing and proposed diagnostic products are regulated by the United States Food and Drug Administration ('FDA'), United States Department of Agriculture ('USDA'), certain state and local agencies, and/or comparable regulatory bodies in other countries.

Ratios

vs
industry
vs
history
P/B 7.26
CEMI's P/B is ranked lower than
74% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.59 vs. CEMI: 7.26 )
Ranked among companies with meaningful P/B only.
CEMI' s P/B Range Over the Past 10 Years
Min: 1.39  Med: 3.02 Max: 20.71
Current: 7.26
1.39
20.71
P/S 3.13
CEMI's P/S is ranked higher than
57% of the 176 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.28 vs. CEMI: 3.13 )
Ranked among companies with meaningful P/S only.
CEMI' s P/S Range Over the Past 10 Years
Min: 0.17  Med: 1.32 Max: 3.99
Current: 3.13
0.17
3.99
POCF 624.55
CEMI's POCF is ranked lower than
99% of the 77 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.72 vs. CEMI: 624.55 )
Ranked among companies with meaningful POCF only.
CEMI' s POCF Range Over the Past 10 Years
Min: 6.11  Med: 25.08 Max: 1820
Current: 624.55
6.11
1820
Current Ratio 2.94
CEMI's Current Ratio is ranked higher than
56% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. CEMI: 2.94 )
Ranked among companies with meaningful Current Ratio only.
CEMI' s Current Ratio Range Over the Past 10 Years
Min: 0.01  Med: 3.1 Max: 58
Current: 2.94
0.01
58
Quick Ratio 1.95
CEMI's Quick Ratio is ranked lower than
57% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. CEMI: 1.95 )
Ranked among companies with meaningful Quick Ratio only.
CEMI' s Quick Ratio Range Over the Past 10 Years
Min: 0.01  Med: 2.34 Max: 58
Current: 1.95
0.01
58
Days Inventory 108.01
CEMI's Days Inventory is ranked lower than
58% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 88.25 vs. CEMI: 108.01 )
Ranked among companies with meaningful Days Inventory only.
CEMI' s Days Inventory Range Over the Past 10 Years
Min: 58.96  Med: 73.57 Max: 108.01
Current: 108.01
58.96
108.01
Days Sales Outstanding 78.95
CEMI's Days Sales Outstanding is ranked lower than
63% of the 157 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 66.25 vs. CEMI: 78.95 )
Ranked among companies with meaningful Days Sales Outstanding only.
CEMI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 26.72  Med: 62.72 Max: 116.23
Current: 78.95
26.72
116.23
Days Payable 41.36
CEMI's Days Payable is ranked lower than
61% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 58.55 vs. CEMI: 41.36 )
Ranked among companies with meaningful Days Payable only.
CEMI' s Days Payable Range Over the Past 10 Years
Min: 30.35  Med: 42.23 Max: 206.77
Current: 41.36
30.35
206.77

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 46.70
CEMI's 3-Year Average Share Buyback Ratio is ranked higher than
99% of the 123 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.70 vs. CEMI: 46.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CEMI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -244.7  Med: -87.95 Max: 46.7
Current: 46.7
-244.7
46.7

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 9.68
CEMI's Price/Net Current Asset Value is ranked higher than
54% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.40 vs. CEMI: 9.68 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CEMI' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.2  Med: 5.64 Max: 37.33
Current: 9.68
2.2
37.33
Price/Tangible Book 7.31
CEMI's Price/Tangible Book is ranked lower than
55% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.42 vs. CEMI: 7.31 )
Ranked among companies with meaningful Price/Tangible Book only.
CEMI' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.58  Med: 3.84 Max: 20
Current: 7.31
1.58
20
Price/Projected FCF 98.14
CEMI's Price/Projected FCF is ranked lower than
99% of the 67 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. CEMI: 98.14 )
Ranked among companies with meaningful Price/Projected FCF only.
CEMI' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.49  Med: 4.04 Max: 117
Current: 98.14
1.49
117
Price/Median PS Value 2.37
CEMI's Price/Median PS Value is ranked lower than
90% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.98 vs. CEMI: 2.37 )
Ranked among companies with meaningful Price/Median PS Value only.
CEMI' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.18  Med: 1.03 Max: 135.06
Current: 2.37
0.18
135.06
Earnings Yield (Greenblatt) (%) -5.70
CEMI's Earnings Yield (Greenblatt) (%) is ranked lower than
60% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.30 vs. CEMI: -5.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CEMI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -5.7  Med: 4.4 Max: 12128.3
Current: -5.7
-5.7
12128.3

More Statistics

Revenue (TTM) (Mil) $21.18
EPS (TTM) $ -1.01
Beta1.43
Short Percentage of Float0.98%
52-Week Range $3.33 - 9.40
Shares Outstanding (Mil)11.99

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 18 26 35
EPS ($) -0.63 -0.26 0.06
EPS w/o NRI ($) -0.63 -0.26 0.06
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for CEMI

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
CHEMBIO DIAGNOSTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Aug 25 2016
Chembio Awarded Up to $13.2 Million U.S. Government Contract to Develop and Commercialize... Aug 25 2016
Chembio Awarded Up to $13.2 Million U.S. Government Contract to Develop and Commercialize... Aug 25 2016
CHEMBIO DIAGNOSTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Aug 18 2016
CHEMBIO DIAGNOSTICS, INC. Financials Aug 18 2016
Chembio Expands Product Distribution through Exclusive Agreement with Isla Lab in the Caribbean Aug 18 2016
Chembio Expands Product Distribution through Exclusive Agreement with Isla Lab in the Caribbean Aug 18 2016
CEMI: Significant Growth Opportunity in Fever Accelerating Shift From STD Aug 16 2016
Chembio Diagnostics, Inc. :CEMI-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 Aug 12 2016
Chembio Diagnostics Reports Second Quarter 2016 Financial Results Aug 11 2016
Chembio Diagnostics Reports Second Quarter 2016 Financial Results Aug 11 2016
CHEMBIO DIAGNOSTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Aug 11 2016
CHEMBIO DIAGNOSTICS, INC. Files SEC form 10-Q, Quarterly Report Aug 11 2016
Q2 2016 Chembio Diagnostics Inc Earnings Release - Before Market Open Aug 11 2016
Investor Calendar Invites You to the Chembio Second Quarter 2016 Earnings Conference Call and... Aug 10 2016
CHEMBIO DIAGNOSTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Aug 04 2016
Chembio to Host Conference Call to Discuss Second Quarter 2016 Financial Results Aug 04 2016
Chembio to Host Conference Call to Discuss Second Quarter 2016 Financial Results Aug 04 2016
CHEMBIO DIAGNOSTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 03 2016
Chembio Diagnostics, Inc. Announces Closing of Offering and Underwriters' Full Exercise of... Aug 03 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)